DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

Information source: Bioprojet
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Narcolepsy; Cataplexy; Excessive Daytime Sleepiness

Intervention: BF2.649 (Drug); BF2.649 add on Modafinil (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Bioprojet

Official(s) and/or principal investigator(s):
Claudio Bassetti, Principal Investigator, Affiliation: Neurocenter of Southern Switzerland,Lugano

Summary

The objective of this study is to evaluate and compare the efficacy and safety of escalating doses of BF2. 649 and BF2. 649 add on Modafinil on cataplexy in patients with narcolepsy

Clinical Details

Official title: Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Cataplexy attacks reported on sleep diary

Secondary outcome:

Sleep Diary: number and duration of diurnal sleep and sleepiness episodes,

Maintenance of Wakefulness Test (MWT), Test of Sustained Attention to Response Task (SART).

Epworth Sleepiness Scale (ESS)

Detailed description: BF 2. 649, a new molecule, reduces significantly the diurnal sleepiness and demonstrated its anti-cataplexy effect in pre-clinical and clinical studies. The objective of this POC study are firstly to evaluate and compare the efficacy and safety of escalating doses of BF2. 649 and BF2. 649 add on Modafinil (200 mg/day) on cataplexy attacks, and secondly to evaluate the additive/synergistic effect and safety of the combination of BF2. 649 and Modafinil on EDS as assessed by both of objective and subjective measures including ESS, MWT, patients sleep diary.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- "De novo" patients with newly diagnosed narcolespy and cataplexy , and not taking any

treatment for Excessive Daytime Sleepiness(EDS) and cataplexy

- patients with previously diagnosed narcolepsy and cataplexy and not taking any

treatment for EDS and cataplexy for more than 3 months

- partial or total cataplexy attacks with a frequency of at least 5 per week during a

14 day baseline period and ESS >or= 14 at the end of the baseline period Exclusion Criteria:

- Patients who are unable or unwilling to temporarily discontinue any no-authorized

drugs or substances

- Current or recent history of a substance abuse or dependence disorder including

alcohol abuse

- Psychiatric and neurological disorders such as psychosis or dementia, bipolar

illness, severe anxiety, clinical depression, history of seizure disorder or other problem that in the investigator's opinion would preclude the patient's participation

Locations and Contacts

Neurocenter (EOC) of Southern Switzerland, Lugano 6903, Switzerland
Additional Information

Starting date: October 2009
Last updated: February 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017